Exhibit 99.1 QIAGEN N.V. and Subsidiaries U.S. GAAP Quarterly Report for the Period Ended September 30, 2024 Table of Contents Condensed Consolidated Financial Statements 2 Condensed Consolidated Balance Sheets as of September 30, 2024 (unaudited) and December 31, 2023 4 Condensed Consolidated Statements of Income (Loss) (unaudited) for the three and nine months ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Comprehensive Income (unaudited) for the three and nine months ended Septe ...

Financial Data and Key Metrics - Q3 2024 sales reached $502 million, representing 6% growth at constant exchange rates (CER), exceeding the outlook of at least $495 million [5] - Adjusted diluted EPS was $0.57, $0.03 above the outlook of at least $0.55 [5] - Adjusted operating income margin improved by 3% to 29.6% of sales compared to Q3 2023 [7] - Free cash flow increased by 73% to $364 million in the first nine months of 2024 [7] - Full-year 2024 net sales outlook reaffirmed at $1.985 billion at CER, with adjusted EPS target increased to at least $2.19 at CER [7] Business Line Performance - Diagnostic Solutions product group grew 10% CER, driven by strong demand for QuantiFERON TB test and QIAstat-Dx [5][10] - QIAstat-Dx sales grew 40% CER, with over 150 instrument placements in Q3 [5] - PCR product group saw double-digit CER growth in consumables, particularly for QIAcuity digital PCR system [10] - Genomics NGS product group sales remained unchanged compared to Q3 2023 [10] - Digital Insights business declined at a low single-digit CER rate due to the transition to SaaS subscription contracts [11] Regional Performance - Europe, Middle East, and Africa (EMEA) region sales rose 8% CER, with strong performance in France and Italy [11] - Americas sales grew 6% CER, driven by solid consumables growth offsetting lower instrument sales [11] - Asia Pacific and Japan region sales declined 2% CER, with China continuing to decline at a high single-digit rate [11] Strategic Direction and Industry Competition - QIAGEN is focusing on expanding its portfolio in liquid biopsy, precision medicine, and syndromic testing [6][15] - The company is transitioning its Digital Insights business to a SaaS model to align with customer preferences [11][44] - QIAGEN is investing in automation and new instrument launches to drive growth in sample technologies [9][50] - The company is leveraging partnerships with pharmaceutical companies like AstraZeneca and Eli Lilly to expand its precision medicine applications [6] Management Commentary on Operating Environment and Future Outlook - Management highlighted the challenging macro environment but expressed confidence in achieving 2024 targets due to strong recurring revenues [4][7] - The company is well-positioned for future growth, with a focus on delivering on its 2028 commitments [7][19] - Management emphasized the importance of innovation and efficiency in driving profitability and cash flow [7][12] Other Important Information - QIAGEN received FDA clearances for QIAstat panels, including the meningitis/encephalitis panel [5] - The company is discontinuing the NeuMoDx system by 2025, which is expected to improve margins [7][25] - QIAGEN raised $500 million through a convertible bond issuance to support strategic growth initiatives and repay debt [14] Q&A Session Summary Question: Sustainability of QuantiFERON growth - QuantiFERON growth is driven by the conversion from skin tests, partnerships with DiaSorin, and inclusion in national TB testing guidelines [22] - The company targets $600 million in QuantiFERON revenues by 2028, with a projected 6-7% CAGR [22] Question: Growth outlook for 2025 - Management expects continued growth in 2025, driven by momentum in QIAstat, QuantiFERON, and sample technologies [24] - Margin expansion is expected to continue, with NeuMoDx discontinuation contributing to improvements [25] Question: QIAstat placements and competitive dynamics - QIAstat placements exceeded 150 in Q3, with growth driven by menu expansion and competitive positioning in the US [27] - The company expects to achieve $200 million in QIAstat revenues by 2028 [27] Question: Capital deployment and M&A strategy - QIAGEN remains active in both share buybacks and M&A, with a focus on value creation and portfolio reinforcement [28] Question: Portfolio mix and growth drivers - The company is confident in its portfolio mix, with growth expected from QIAstat, QIAcuity, and Digital Insights [31][33] Question: Operating margin trajectory - Management sees potential for further margin improvement beyond the 31% target by 2028, driven by efficiency programs and R&D acceleration [34][41] Question: QDI business transition to SaaS - The shift to SaaS is a customer-driven trend, with no change in the volume of contracts or growth ambitions [44] Question: Sample prep performance and outlook - Sample technologies are expected to grow above market rates, driven by automation and new instrument launches [50] Question: NeuMoDx wind-down impact - NeuMoDx revenues are expected to phase out by H2 2025, with no significant contribution beyond Q2 2025 [52] Question: Instrument revenue outlook - Instrument revenue is expected to improve sequentially in Q4, though overall growth remains negative [55] Question: Liquid biopsy growth contribution - QIAGEN is a key enabler in the liquid biopsy market, with growth expected from oncology and other applications [56] Question: Impact of US election and tariffs - The company is monitoring potential policy changes but remains confident in its global presence and US market position [58][59]

Core Insights - QIAGEN N.V. reported third-quarter 2024 adjusted earnings per share (EPS) of 57 cents, a 14% increase from the previous year, exceeding the Zacks Consensus Estimate by 5.6% [1][2] - The company's quarterly net sales rose 5.5% year over year to $501.9 million, beating the Zacks Consensus Estimate by 2.3% [3] - QIAGEN's operational efficiency and market share gains were highlighted, despite margin contractions [13][14] Financial Performance - Adjusted gross profit decreased by 0.5% year over year to $316.1 million, with an adjusted gross margin of 62.9%, down 374 basis points [7][8] - Adjusted operating income increased by 1.2% year over year to $131 million, while the adjusted operating margin contracted to 26.1% [8] - The company ended the quarter with cash and short-term investments of $1.5 billion, up from $1.1 billion in the previous quarter [10] Segment Performance - Sample technologies revenues increased by 1% to $162 million, while diagnostic solutions revenues rose by 10% to $197 million [4] - PCR / Nucleic acid amplification revenues grew by 9% to $74 million, and genomics / NGS revenues remained stable at $55 million [5][6] - Other revenues decreased by 3% year over year to $14 million [6] Outlook - For the full year, QIAGEN expects net sales of at least $1.985 billion, with adjusted EPS projected at a minimum of $2.19 [11] - The company anticipates fourth-quarter net sales of at least $520 million and adjusted EPS of at least 60 cents [12] Strategic Developments - QIAGEN launched 100 new assays for the QIAcuity digital PCR system and expanded the QIAstat-Dx system's utility through partnerships with AstraZeneca and Eli Lilly [14]

Qiagen (QGEN) reported $501.87 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 5.5%. EPS of $0.57 for the same period compares to $0.52 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $490.53 million, representing a surprise of +2.31%. The company delivered an EPS surprise of +5.56%, with the consensus EPS estimate being $0.54.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Qiagen (QGEN) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.52 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.56%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.52 per share when it actually produced earnings of $0.55, delivering a surprise of 5.77%.Over the last four quarters, the c ...

FDA Clearance and Product Innovation - The US FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use, marking the fourth QIAstat-Dx syndromic test to receive US regulatory clearance in 2024 [1] - The QIAstat-Dx Meningitis/Encephalitis Panel leverages real-time PCR technology to simultaneously analyze multiple genetic targets, providing results in about one hour, compared to traditional methods that require at least 24 hours [2][3] - The QIAstat-Dx system provides cycle threshold (Ct) values and amplification curves, offering additional clinical information not available with traditional end-point PCR or other techniques [4] Market and Industry Context - Bacterial meningitis cases in the US have reached their highest levels since 2014, with case numbers varying by state depending on vaccination rates [2] - Many US healthcare facilities still rely on traditional microbiological testing, which lacks sensitivity and requires longer processing times [2] - The QIAstat-Dx system addresses the need for rapid, evidence-based diagnostics in community-acquired meningitis and encephalitis, which are medical emergencies requiring immediate treatment [3] Product Portfolio and Operational Efficiency - The QIAstat-Dx Meningitis/Encephalitis Panel is the fourth FDA-cleared QIAstat-Dx panel in 2024, following clearances for the Gastrointestinal Panel 2, Respiratory Panel Plus, and Respiratory Panel Mini [4] - All QIAstat-Dx panels are available as cost-efficient, single-use cartridges that simplify test setup, requiring less than a minute and no precision pipetting [4] - The system’s software interprets signals from the reaction and provides positive or negative results for each pathogen, offering one of the simplest workflows for syndromic testing on the market [4] Company Overview - QIAGEN is a Netherlands-based holding company and a leading global provider of Sample to Insight solutions, enabling molecular insights from biological samples [6] - The company serves over 500,000 customers worldwide in Molecular Diagnostics and Life Sciences, with more than 5,900 employees across over 35 locations as of June 30, 2024 [6][7]

Germantown, Maryland, and Venlo, the Netherlands, Oct. 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA clearance for use with QIAstat-Dx systems in 2024. The QIAstat-Dx Respiratory Panel Mini is designed to support clinical decision making in diagnosing upper respiratory infections in outpatient settings ...

QIAGEN N.V. (QGEN) is well-poised to grow in the coming quarter, driven by its strategic alliances with researchers and pharma companies. The company's expansive next-generation sequencing (NSG) portfolio continues to be bolstered by several innovations. Meanwhile, QIAGEN's operations are vulnerable to currency fluctuations, which can adversely affect its financial results. Competitive disadvantages also add to the worry. In the past year, this Zacks Rank #3 (Hold) stock has risen 6% compared with 4% growth ...

Venlo, the Netherlands, Sept. 26, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAstat-Dx syndromic testing systems and associated assays have received CE-marking under the European Union's new In-Vitro Diagnostic Medical Devices Regulation (IVDR). This certification includes the widely-used QIAstat-Dx Analyzer, QIAstat-Dx Rise, and panels for detecting gastrointestinal and respiratory illnesses. The achievement underscores QIAGEN's commitment to meeti ...

QIAGEN N.V.(QGEN) and Becton, Dickinson and Company or BD's (BDX) joint venture, PreAnalytiX GmbH, recently launched the PAXgene Urine Liquid Biopsy Set. PAXgene will be used for reliable analysis of cell-free DNA (cfDNA) from urine with most molecular testing technologies, including qPCR, digital PCR and next-generation sequencing (NGS). QIAGEN will commercialize the newly launched set with the first verified, standardized and complete preanalytical workflow from urine collection, stabilization and isolati ...